| Value | Category | Cases | |
|---|---|---|---|
| Entry Required | 5 |
5.4%
|
|
| Lipodystrophy | 7 |
7.5%
|
|
| Other | 40 |
43%
|
|
| Policy change | 20 |
21.5%
|
|
| Poor adherence | 7 |
7.5%
|
|
| Renal impairment | 1 |
1.1%
|
|
| TasP trial switch to Atripla | 4 |
4.3%
|
|
| Virological failure | 9 |
9.7%
|